Trials / Completed
CompletedNCT01165502
Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers
Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- CellMed AG, a subsidiary of BTG plc. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM3.1-AC100 | MAD study with repeated subcutaneous (sc) doses |
| DRUG | Placebo | Placebo for compound CM3.1-AC100 s.c. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-07-20
- Last updated
- 2011-01-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01165502. Inclusion in this directory is not an endorsement.